EXACT SCIENCES CORP (EXAS) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, EXACT SCIENCES CORP's filing signal continuing positive.

Exact Sciences Corporation is a leading provider of cancer screening and diagnostic tests, aiming to empower patients and healthcare professionals with early, actionable insights. The company's portfolio includes the Cologuard and Cologuard Plus stool-based DNA tests for colorectal cancer screening, and precision oncology tests like Oncotype DX for breast and colon cancer recurrence risk assessment. In 2025, Exact Sciences launched Cancerguard, a multi-cancer early detection blood test, and Oncodetect, a molecular residual disease (MRD) test. The company is also advancing its pipeline with new blood-based screening tests and expanding its international reach for its Oncotype tests. Exact Sciences operates under an agreement to be acquired by Abbott Laboratories, expected to close in the second quarter of 2026.

Revenue is primarily driven by the volume of completed Cologuard and Cologuard Plus tests, and the number of completed Oncotype DX breast cancer tests, both domestically and internationally. Growth is also supported by new ordering providers and international expansion, particularly in Japan.